Progress in metallocarboxypeptidases and their small molecular weight inhibitors
Daniel Fernández1, Irantzu Pallarès, Josep Vendrell
1Departament de Bioquímica i Biologia Molecular, Facultat de Biociències and Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.
Biochimie
|May 15, 2010
Summary
Metallocarboxypeptidases (MCPs) are vital zinc-dependent enzymes involved in numerous physiological processes and diseases. This review highlights recent advances in discovering small molecule inhibitors for therapeutic applications.
Area of Science:
- Biochemistry
- Enzymology
- Drug Discovery
Background:
- Metallocarboxypeptidases (MCPs) are zinc-dependent enzymes crucial for physiological processes like amino acid recovery, organogenesis, and maturation of hormones and cytokines.
- Over 26 human genes encode MCPs, many with functions yet to be fully elucidated.
- MCPs are implicated in various human diseases, including pancreatitis, cancer, type 2 diabetes, Alzheimer's disease, and inflammatory/coagulation disorders.
Purpose of the Study:
- To review key developments in the discovery and design of small molecular weight inhibitors targeting metallocarboxypeptidases (MCPs).
- To emphasize the discovery of chemically diverse entities for therapeutic applications.
- To discuss challenges in achieving specificity and oral bioavailability for new chemotherapeutic agents.
Main Methods:
- Review of recent advances in understanding MCP structure and function, exemplified by plasma carboxypeptidases N and B.
- Analysis of the development of small molecular weight inhibitors, using carboxypeptidase A as a benchmark.
- Exploration of MCPs as drug targets in pharmaceutical and academic research.
Main Results:
- Recent structural data for plasma carboxypeptidases have enabled therapeutic targeting.
- A diverse range of small molecule inhibitors for MCPs has been identified and designed.
- Significant progress has been made in developing MCP inhibitors for various diseases.
Conclusions:
- Metallocarboxypeptidases (MCPs) have evolved from contaminants to critical targets in drug discovery.
- The development of MCP inhibitors shows promise for treating diseases linked to these enzymes.
- Challenges remain in optimizing inhibitor specificity and oral bioavailability for clinical application.
Related Concept Videos
01:23Inhibitors of Gram-positive Cell Wall Synthesis
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...